Suppr超能文献

酚类乙二胺衍生物:口服有效的铁螯合剂的研究

Phenolic ethylenediamine derivatives: a study of orally effective iron chelators.

作者信息

Hershko C, Grady R W, Link G

出版信息

J Lab Clin Med. 1984 Mar;103(3):337-46.

PMID:6699459
Abstract

Of 35 potential iron chelators screened for in vivo activity in rats, a group of phenolic compounds with excellent chelating properties were identified. These included N,N'-ethylene-bis(o-hydroxyphenylglycine) (EHPG), N,N'-Bis(o-hydroxybenzyl)-ethylenediamine diacetic acid (HBED), and their respective dimethyl esters (dmEHPG and dmHBED). All four phenolic compounds produced a marked increase in the fecal excretion of hepatocellular radioiron. This amounted to 42% of total body radioactivity with dmEHPG, 58% with EHPG, 63% with HBED, and 80% with dmHBED after a single injection of 40 mg/animal. At a dose of 5 mg/animal, EHPG, HBED, and dmHBED were 9, 12, and 15 times more potent, respectively, than deferoxamine. Both dimethyl esters showed significant oral activity; oral dmEHPG retained 1/3 and dmHBED retained 2/3 of the effect of the same dose given by intramuscular injection. The ester dmHBED combines oral effectiveness with superior chelating ability, selective hepatocellular action, and low apparent toxicity. It may represent a significant advance in the development of new iron chelating drugs.

摘要

在对35种潜在的铁螯合剂进行大鼠体内活性筛选时,鉴定出了一组具有优异螯合特性的酚类化合物。这些化合物包括N,N'-亚乙基双(邻羟基苯甘氨酸)(EHPG)、N,N'-双(邻羟基苄基)乙二胺二乙酸(HBED)及其各自的二甲酯(dmEHPG和dmHBED)。所有这四种酚类化合物均使肝细胞放射性铁的粪便排泄量显著增加。单次注射40mg/只动物后,dmEHPG使粪便排泄量占全身放射性的42%,EHPG为58%,HBED为63%,dmHBED为80%。在剂量为5mg/只动物时,EHPG、HBED和dmHBED的效力分别比去铁胺高9倍、12倍和15倍。两种二甲酯均显示出显著的口服活性;口服dmEHPG保留了肌肉注射相同剂量效果的1/3,dmHBED保留了2/3。酯类dmHBED兼具口服有效性、卓越的螯合能力以及选择性肝细胞作用和低表观毒性。它可能代表了新型铁螯合药物开发的重大进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验